It has been proposed that nanoparticles demonstrated increased cytotoxicity by ‘enhanced permeation and retention’ (EPR) relative to the parent polymer through which they tend to be accumulated at the tumor sites, delivering better responses with less deleterious effects. Importantly, tumor is accompanied with acidosis and tumor microenvironment will follow a drastic drop in pH compared with the surrounding niche. Hence, in the case of hydrophilic polymers like PST001, EPR will enable the accumulation of PST-Dox nanoparticles and release of Dox preferentially at the tumor target sites. This aspect was noticed

with the release kinetics performed on human cancer cell lines such as HCT116, MCF-7 and K562 for the measurement of intracellular Dox. Also, both the Venetoclax confocal measurement and

flurimetric estimation clearly demonstrate the increased accumulation of Dox from the PST-Dox nanoparticles compared to the naked Dox-Hcl. Prolongation of lifespan in animals with an ILS exceeding 25% indicated antitumor effectiveness of a drug as per NCI criteria [25]. The tumor reduction exhibited by PST-Dox nanoparticle was higher than the clinically used counterpart Dox, and the overall survival was also the longest than many known chemotherapeutics. This superior effect combined with less toxicity could be http://www.selleckchem.com/HSP-90.html attributed to the already reported immunomodulatory effects of PST001 [22] in the nanoparticle formulation. Most chemotherapeutic agents have serious side-effects which limit their widespread clinical applications, warranting the need for anticancer agents that are non-toxic to normal cells. We recently reported the tumor Progesterone specificity and reduction in the Dox organ-related toxicity in galactoxyloglucan-Dox conjugated nanoparticles

[26]. In the current study also, there were no observable side-effects upon administration of the parent polysaccharide as well as its nanoparticle derivative, which justifies their unique drug utility. PST-Dox nanoparticles maintained the safety profile of the immunostimulatory polysaccharide, PST001 while eliciting anticancer potential of both Dox and PST001. Thus, our data suggests that PST-Dox nanoparticle is a better alternative to the clinically available Dox in all the aspects, with respect to limiting both solid and ascites tumors. This study demonstrates the promising anticancer potential of a nanoparticle aggregate of doxorubicin, PST-Dox. Galactoxyloglucan nanoparticles carrying the Dox moiety significantly decreased cell viability of murine ascites by the induction of apoptosis in the monolayer culture. The cellular uptake of the PST-Dox also showed encouraging results in the colon and breast cancer cells compared to the uptake from the free Dox.